All questions
Real-world evidence: Paxlovid (nirmatrelvir; ritonavir) in COVID-19
2 questions · 2 sources
Questions that apply to every indication of Paxlovid are on Paxlovid (nirmatrelvir; ritonavir), all indications.
Real-world evidence
What did a real-world study (Lewnard) show for Paxlovid and hospitalization?
Note: This retrospective cohort study (Lewnard JA, et al. Lancet Infect Dis. 2023) is presented on the Paxlovid HCP site. Its inclusion criteria admitted patients 12 years and older; Paxlovid is approved for adults. The inclusion criteria listed on the page do not require a risk factor for severe COVID-19. The page lists further study limitations, including incomplete capture of variables and possible unmeasured confounding.
Does Paxlovid work in vaccinated patients in a real-world study (Lewnard)?
Note: The study (Lewnard JA, et al. Lancet Infect Dis. 2023) analyzed Kaiser Permanente Southern California patients with a positive SARS-CoV-2 test between April 8 and October 7, 2022. The primary endpoint was hospital admission or death from any cause within 30 days. Its inclusion criteria admitted patients 12 years and older and did not require a risk factor for severe COVID-19; Paxlovid is approved for adults at high risk.